p53 immunochemistry is an independent prognostic marker for outcome in conservatively treated prostate cancer

Sak Kudahetti; Gabrielle Fisher; Laurence Ambroisine; Christopher Foster; Victor Reuter; James Eastham; Henrik Møller; Michael W Kattan; Colin S Cooper; Peter Scardino; Jack Cuzick; Daniel M Berney

doi:10.1111/j.1464-410X.2009.08407.x

p53 immunochemistry is an independent prognostic marker for outcome in conservatively treated prostate cancer

Sak Kudahetti, Gabrielle Fisher, Laurence Ambroisine, Christopher Foster, Victor Reuter, James Eastham, Henrik Møller, Michael W Kattan, Colin S Cooper, Peter Scardino, Jack Cuzick, Daniel M Berney

Research output: Contribution to journal › Article › peer-review

31 Citations (Scopus)

Abstract

OBJECTIVE To determine whether p53 is an independent biomarker of prostate cancer outcome against currently used biomarkers in a cohort of conservatively treated prostate cancers with long-term follow-up available. PATIENTS AND METHODS We examined p53 expression by immunohistochemistry in a cohort of 705 patients with clinically localized prostate cancer, who were treated conservatively. Patients were selected through UK Cancer Registries. End-points included prostate cancer death and overall death rates. Standard biological variables, including diagnostic serum PSA, contemporary Gleason scoring, clinical staging and cancer extent were available. p53 expression was measured semi-quantitatively on microscopic examination and compared with current clinical biomarkers. RESULTS p53 over expression was a significant predictor of cause-specific survival (hazard ratio [HR] 2.95, 95% CI 2.05-4.25, P

Original language	English
Pages (from-to)	20-4
Number of pages	5
Journal	BJU International
Volume	104
Issue number	1
DOIs	https://doi.org/10.1111/j.1464-410X.2009.08407.x
Publication status	Published - Jul 2009

Keywords

Aged
Cohort Studies
Humans
Immunohistochemistry
Male
Middle Aged
Multivariate Analysis
Prognosis
Prostatic Neoplasms
Survival Analysis
Tumor Markers, Biological
Tumor Suppressor Protein p53

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1111/j.1464-410X.2009.08407.x

Cite this

@article{2f55e8947f9042ad9ddcc9fb89a5c71d,

title = "p53 immunochemistry is an independent prognostic marker for outcome in conservatively treated prostate cancer",

abstract = "OBJECTIVE To determine whether p53 is an independent biomarker of prostate cancer outcome against currently used biomarkers in a cohort of conservatively treated prostate cancers with long-term follow-up available. PATIENTS AND METHODS We examined p53 expression by immunohistochemistry in a cohort of 705 patients with clinically localized prostate cancer, who were treated conservatively. Patients were selected through UK Cancer Registries. End-points included prostate cancer death and overall death rates. Standard biological variables, including diagnostic serum PSA, contemporary Gleason scoring, clinical staging and cancer extent were available. p53 expression was measured semi-quantitatively on microscopic examination and compared with current clinical biomarkers. RESULTS p53 over expression was a significant predictor of cause-specific survival (hazard ratio [HR] 2.95, 95% CI 2.05-4.25, P ",

keywords = "Aged, Cohort Studies, Humans, Immunohistochemistry, Male, Middle Aged, Multivariate Analysis, Prognosis, Prostatic Neoplasms, Survival Analysis, Tumor Markers, Biological, Tumor Suppressor Protein p53",

author = "Sak Kudahetti and Gabrielle Fisher and Laurence Ambroisine and Christopher Foster and Victor Reuter and James Eastham and Henrik M{\o}ller and Kattan, {Michael W} and Cooper, {Colin S} and Peter Scardino and Jack Cuzick and Berney, {Daniel M}",

year = "2009",

month = jul,

doi = "10.1111/j.1464-410X.2009.08407.x",

language = "English",

volume = "104",

pages = "20--4",

journal = "BJU International",

issn = "1464-4096",

publisher = "Wiley",

number = "1",

}

TY - JOUR

T1 - p53 immunochemistry is an independent prognostic marker for outcome in conservatively treated prostate cancer

AU - Kudahetti, Sak

AU - Fisher, Gabrielle

AU - Ambroisine, Laurence

AU - Foster, Christopher

AU - Reuter, Victor

AU - Eastham, James

AU - Møller, Henrik

AU - Kattan, Michael W

AU - Cooper, Colin S

AU - Scardino, Peter

AU - Cuzick, Jack

AU - Berney, Daniel M

PY - 2009/7

Y1 - 2009/7

N2 - OBJECTIVE To determine whether p53 is an independent biomarker of prostate cancer outcome against currently used biomarkers in a cohort of conservatively treated prostate cancers with long-term follow-up available. PATIENTS AND METHODS We examined p53 expression by immunohistochemistry in a cohort of 705 patients with clinically localized prostate cancer, who were treated conservatively. Patients were selected through UK Cancer Registries. End-points included prostate cancer death and overall death rates. Standard biological variables, including diagnostic serum PSA, contemporary Gleason scoring, clinical staging and cancer extent were available. p53 expression was measured semi-quantitatively on microscopic examination and compared with current clinical biomarkers. RESULTS p53 over expression was a significant predictor of cause-specific survival (hazard ratio [HR] 2.95, 95% CI 2.05-4.25, P

AB - OBJECTIVE To determine whether p53 is an independent biomarker of prostate cancer outcome against currently used biomarkers in a cohort of conservatively treated prostate cancers with long-term follow-up available. PATIENTS AND METHODS We examined p53 expression by immunohistochemistry in a cohort of 705 patients with clinically localized prostate cancer, who were treated conservatively. Patients were selected through UK Cancer Registries. End-points included prostate cancer death and overall death rates. Standard biological variables, including diagnostic serum PSA, contemporary Gleason scoring, clinical staging and cancer extent were available. p53 expression was measured semi-quantitatively on microscopic examination and compared with current clinical biomarkers. RESULTS p53 over expression was a significant predictor of cause-specific survival (hazard ratio [HR] 2.95, 95% CI 2.05-4.25, P

KW - Aged

KW - Cohort Studies

KW - Humans

KW - Immunohistochemistry

KW - Male

KW - Middle Aged

KW - Multivariate Analysis

KW - Prognosis

KW - Prostatic Neoplasms

KW - Survival Analysis

KW - Tumor Markers, Biological

KW - Tumor Suppressor Protein p53

U2 - 10.1111/j.1464-410X.2009.08407.x

DO - 10.1111/j.1464-410X.2009.08407.x

M3 - Article

C2 - 19239456

VL - 104

SP - 20

EP - 24

JO - BJU International

JF - BJU International

SN - 1464-4096

IS - 1

ER -